Physician profile
James Cherry
NPI 1114945672
$3,551.33
in general payments reported to CMS, 2019-2025
34 companies · $404 in 2025
The $404 reported for 2025 was less than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $534 · 2020: $450 · 2021: $583 · 2022: $1,190 · 2023: $236 · 2024: $155 · 2025: $404.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $795.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $795.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $635.00 | 2019-2023 | Erleada |
| Astellas Pharma US INC | $395.77 | 2019-2022 | |
| Teleflex LLC | $330.34 | 2022-2025 | Barrigel |
| 180 Medical, INC. | $211.42 | 2019-2021 | |
| Endo Pharmaceuticals INC. | $207.79 | 2020-2023 | Xiaflex |
| Urovant Sciences INC | $168.61 | 2021-2022 | |
| Procept Biorobotics Corporation | $155.38 | 2024 | Aquabeam System |
| Stryker Corporation | $135.78 | 2025 | 1788 |
| Calyxo, INC. | $119.49 | 2025 | Cvac Aspiration System |
| Merck Sharp & Dohme LLC | $115.82 | 2020-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $113.92 | 2022 | |
| Olympus America INC. | $112.75 | 2019-2022 | |
| Allergan, INC. | $105.23 | 2019-2021 | |
| Progenics Pharmaceuticals, INC. | $100.00 | 2022 | |
| Abbvie INC. | $70.58 | 2022 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coloplast Corp | $65.46 | 2022-2023 | Porges Coloplast |
| Sumitomo Pharma America, INC. | $57.58 | 2023 | Gemtesa |
| Myovant Sciences INC. | $52.53 | 2021-2022 | |
| Laborie Medical Technologies Corp. | $52.51 | 2021-2023 | |
| Tolmar Pharmaceuticals, INC. | $46.49 | 2020-2021 | |
| Mallinckrodt Enterprises LLC | $45.43 | 2019 | |
| Boston Scientific Corporation | $30.97 | 2019 | |
| Cook Medical LLC | $27.90 | 2019-2021 | |
| Axonics, INC. | $25.86 | 2022 | |
| Alnylam Pharmaceuticals INC. | $21.25 | 2021 | |
| Clovis Oncology, INC. | $20.49 | 2021 | |
| Blue Earth Diagnostics | $20.38 | 2020 | |
| Myriad Genetic Laboratories, INC. | $18.40 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $16.69 | 2022 | |
| Foundation Medicine, INC. | $15.89 | 2020 | |
| Astrazeneca Pharmaceuticals Lp | $15.41 | 2022 | |
| Medtronic, INC. | $13.68 | 2022 | |
| Photocure INC | $13.47 | 2021 | |
| Dentsply Ih INC. | $13.06 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Cherry listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.